{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:05:59Z","timestamp":1794002759164,"version":"4.8.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007214","name":"Velux Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008273","name":"\u00d8jenfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022657","name":"Faculdade de Ci\u00eancias da Sa\u00fade, Universidade de Macau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005929","name":"Danish Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012526","name":"University of Aarhus Faculty of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["24OC0088426"],"award-info":[{"award-number":["24OC0088426"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008397","name":"Velux Foundation","doi-asserted-by":"publisher","award":["00038189"],"award-info":[{"award-number":["00038189"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2026.102833","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:09:07Z","timestamp":1768061347000},"page":"102833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["AAV-mediated multiple gene therapy combining VEGFA-targeting miR-agshRNAs and PEDF for the suppression of choroidal neovascularization"],"prefix":"10.1016","volume":"37","author":[{"given":"Bj\u00f8rn K.","family":"Fabian-Jessing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise","family":"Askou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stax","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Lentz","family":"Adsersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B\u00f8gh","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kirstine","family":"K\u00f8llner Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidsel","family":"Alsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toke","family":"Bek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-0439","authenticated-orcid":false,"given":"Lars","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-6350","authenticated-orcid":false,"given":"Thomas J.","family":"Corydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102833_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(08)61759-6","article-title":"Age-related macular degeneration","volume":"372","author":"Coleman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102833_bib3","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.ophtha.2012.11.041","article-title":"Incidence of visual impairment over a 20-year period: the Beaver Dam Eye Study","volume":"120","author":"Klein","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2026.102833_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102833_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/aos.15641","article-title":"Visual acuity and causes of central visual loss in the adult Danish population 2020-2022. Results from the FORSYN study","volume":"101","author":"Bek","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/13548506.2014.936886","article-title":"Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review","volume":"20","author":"Boyle","year":"2015","journal-title":"Psychol. Health Med."},{"key":"10.1016\/j.omtn.2026.102833_bib9","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2026.102833_bib10","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/OPTH.S275977","article-title":"Trends in Real-World Neovascular AMD Treatment Outcomes in the UK","volume":"14","author":"Mehta","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/bjophthalmol-2021-319054","article-title":"Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles","volume":"106","author":"Vofo","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001516","article-title":"Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response-a scoping review","volume":"9","author":"Dervenis","year":"2024","journal-title":"BMJ Open Ophthalmol."},{"key":"10.1016\/j.omtn.2026.102833_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101323","article-title":"Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration","volume":"104","author":"Corydon","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102833_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","article-title":"Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial","volume":"124","author":"Jaffe","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2026.102833_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41434-024-00461-1","article-title":"Stable inhibition of choroidal neovascularization by adeno-associated virus 2\/8-vectored bispecific molecules","volume":"31","author":"Bai","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.102833_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.65.14.1","article-title":"Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies","volume":"65","author":"Calton","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2026.102833_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omtn.2019.01.012","article-title":"Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy","volume":"16","author":"Askou","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102833_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.omtn.2018.11.013","article-title":"Efficient Knockdown and Lack of Passenger Strand Activity by Dicer-Independent shRNAs Expressed from Pol II-Driven MicroRNA Scaffolds","volume":"14","author":"Kaadt","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102833_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.64","article-title":"Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors","volume":"2","author":"Askou","year":"2015","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102833_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/hgtb.2017.079","article-title":"Suppression of Choroidal Neovascularization in Mice by Subretinal Delivery of Multigenic Lentiviral Vectors Encoding Anti-Angiogenic MicroRNAs","volume":"28","author":"Askou","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtn.2026.102833_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101242","article-title":"Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model","volume":"32","author":"Haldrup","year":"2024","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102833_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtn.2022.02.019","article-title":"VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy","volume":"28","author":"Alsing","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102833_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.65.14.41","article-title":"Functional Roles of Pigment Epithelium-Derived Factor in Retinal Degenerative and Vascular Disorders: A Scoping Review","volume":"65","author":"Jakobsen","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2026.102833_bib26","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/gt.2008.147","article-title":"Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs","volume":"15","author":"Aagaard","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.102833_bib27","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/nar\/24.17.3439","article-title":"Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information","volume":"24","author":"Hebsgaard","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.102833_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-2836(91)90380-O","article-title":"Prediction of human mRNA donor and acceptor sites from the DNA sequence","volume":"220","author":"Brunak","year":"1991","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omtn.2026.102833_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cmb.1997.4.311","article-title":"Improved splice site detection in Genie","volume":"4","author":"Reese","year":"1997","journal-title":"J. Comput. Biol."},{"key":"10.1016\/j.omtn.2026.102833_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","article-title":"In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR\/Cas9 in Mouse Retinal Pigment Epithelium Cells","volume":"9","author":"Holmgaard","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102833_bib31","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1038\/s41598-025-93993-4","article-title":"Therapeutic potential of AAV2-shmTOR gene therapy in reducing retinal inflammation and preserving endothelial Integrity in age-related macular degeneration","volume":"15","author":"Kim","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102833_bib32","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1038\/s41598-023-29014-z","article-title":"CRISPR\/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization","volume":"13","author":"Park","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102833_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101366","article-title":"Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration","volume":"32","author":"Shim","year":"2024","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102833_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107939","article-title":"Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration","volume":"26","author":"Wei-Zhang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2026.102833_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on M\u00fcller Cells and Photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.102833_bib36","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102833_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120231","article-title":"VEGF\/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models","volume":"3","author":"Long","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.102833_bib38","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI129861","article-title":"Low risk to retina from sustained suppression of VEGF","volume":"129","author":"Campochiaro","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.102833_bib39","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102833_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2026.102833_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075666","article-title":"Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects","volume":"8","author":"Guziewicz","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.102833_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","article-title":"Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9\/2020","volume":"10","author":"Chan","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.omtn.2026.102833_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature09830","article-title":"DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration","volume":"471","author":"Kaneko","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102833_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107798","article-title":"Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization","volume":"188","author":"Sheibani","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108030","article-title":"Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy","volume":"195","author":"Sheibani","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib47","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102833_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omtn.2026.102833_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int. J. Retina Vitreous"},{"key":"10.1016\/j.omtn.2026.102833_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ymthe.2020.09.032","article-title":"Targeted Knockout of the Vegfa Gene in the Retina by Subretinal Injection of RNP Complexes Containing Cas9 Protein and Modified sgRNAs","volume":"29","author":"Holmgaard","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102833_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1383","article-title":"Nme(2) Cas9-mediated therapeutic editing in inhibiting angiogenesis after wet age-related macular degeneration onset","volume":"13","author":"Hu","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102833_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102833_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101110","article-title":"RNA-targeting strategies as a platform for ocular gene therapy","volume":"92","author":"Kumar","year":"2023","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408345121","article-title":"Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina","volume":"121","author":"Kumar","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102833_bib55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/nsr\/nwaa033","article-title":"CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.omtn.2026.102833_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.omtn.2023.07.018","article-title":"25 years of maturation: A systematic review of RNAi in the clinic","volume":"33","author":"Corydon","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102833_bib57","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-021-25204-3","article-title":"Mirtron-mediated RNA knockdown\/replacement therapy for the treatment of dominant retinitis pigmentosa","volume":"12","author":"Orlans","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102833_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exer.2018.10.009","article-title":"Rapid differentiation of the human RPE cell line, ARPE-19, induced by nicotinamide","volume":"179","author":"Hazim","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtn.2026.102833_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.102833_bib60","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1167\/iovs.14-15067","article-title":"Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation","volume":"55","author":"Poor","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2026.102833_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.898568","article-title":"Simple Autofluorescence-Restrictive Sorting of eGFP+ RPE Cells Allows Reliable Assessment of Targeted Retinal Gene Therapy","volume":"2","author":"Alsing","year":"2022","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.omtn.2026.102833_bib62","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.102833_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Software"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:15:59Z","timestamp":1780103759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253126000041"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102833","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-mediated multiple gene therapy combining VEGFA-targeting miR-agshRNAs and PEDF for the suppression of choroidal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102833"}}